Mid-period crossings: the quarter's story is things that started during it and are still completing
The model's full reasoning — Q2 2023 call → NOWe need to determine if the call describes real business activity that started partway through the period, and management conveys that the reported numbers are below the current run rate because the climb is incomplete. Let's examine the transcript. The CEO mentions strong results, growth drivers. Key points: KEDRAB sales increased, Kedrion extended distribution agreement. Also, they received FDA approval to manufacture CYTOGAM at Israeli facility, and recently got Health Canada approval. They expect to initiate sales of product manufactured in Israeli facility early in Q4. That is a start of manufacturing at a new facility, but sales haven't started yet; they expect to start in Q4. That is a future start, not in the reported period. Also, they are opening a second plasma collection center in Houston in early 2024, that's future. The InnovAATe trial enrollment is ramping, but that's a clinical trial, not revenue-generating activity. The main revenue growth is from KEDRAB sales to Kedrion, which increased due to demand. That is an existing product, existing distribution, just higher demand. No new start. The CYTOGAM manufacturing at Israeli facility is a new capability, but they haven't started selling from it yet; they expect to start in Q4. So that's not yet transacting. Thus, there is no real business activity that crossed from not-happening to happening partway through the period. The call is about strong performance of existing business. Therefore, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AIN | Albany International Corp. | Q3 2023 | 2023-11-07 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
AFL · Q2 2023 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the Japan Post cancer insurance launch in early April, which began selling the product and drove a 60% sales increase as a major contributor. They describe the activity as real and transacting, with Dan Amos noting the significant contribution from the new product. Yoshizumi confirms gradual increase going forward, and Fred highlights runway for more agents and sales calming down after initial jump, indicating the Q2 numbers reflect partial ramp-up rather than full run-rate.
ESE · Q2 2016 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the real mid-period start of Plastique's contribution (acquired partway through Q2, with two months of performance noted and "early performance consistent with our acquisition forecast"), treated as a key new segment. It also explicitly addresses the incomplete climb, noting that the reported Q 2 numbers lag due to partial contribution and that Q3/Q4 will see fuller periods plus seasonality, with the business already running at a higher level as the ramp continues.
PSX · Q4 2016 → YESThe question is about whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the per...YES The transcript shows management centering the Q4 story on the Freeport LPG Export Terminal's real start: commissioning completed smoothly, first commercial cargo shipped mid-December (partial Q4 contribution), with full-quarter costs incurred but only partial revenue, and explicit ramp to near-capacity loading in January onward.